Augmenting Cost-Effectiveness Analysis Will Not Improve Affordability.

Watkins, John B; Tsiao, Emily G · J Manag Care Spec Pharm · 2020

editorial · Level V

Where this comes from

Abstract

No outside funding contributed to this article. The authors are employed by Premera Blue Cross and have nothing to disclose.

Medical subject headings